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reported in the publications show that an increase in MetHb and COHb can happen in COVID-19
patients, especially in critically ill ones, and that MetHb and COHb can increase to dangerously high
levels during the course of the disease in some patients. The medications given to the patient and the
patient’s glucose-6-phospate dehydrogenase (G6PD) status seem to be important factors determining
the severity of the methemoglobinemia and carboxyhemoglobinemia. Therefore, G6PD status should
be determined before medications such as hydroxychloroquine are administered. In conclusion, MetHb
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Abstract: Following the outbreak of a novel coronavirus (SARS-CoV-2) associated with pneumonia
in China (Corona Virus Disease 2019, COVID-19) at the end of 2019, the world is currently facing a
global pandemic of infections with SARS-CoV-2 and cases of COVID-19. Since severely ill patients
often show elevated methemoglobin (MetHb) and carboxyhemoglobin (COHb) concentrations in
their blood as a marker of disease severity, we aimed to summarize the currently available published
study results (case reports and cross-sectional studies) on MetHb and COHb concentrations in the
blood of COVID-19 patients. To this end, a systematic literature research was performed. For the
case of MetHb, seven publications were identified (five case reports and two cross-sectional studies),
and for the case of COHb, three studies were found (two cross-sectional studies and one case report).
The findings reported in the publications show that an increase in MetHb and COHb can happen
in COVID-19 patients, especially in critically ill ones, and that MetHb and COHb can increase to
dangerously high levels during the course of the disease in some patients. The medications given to
the patient and the patient’s glucose-6-phospate dehydrogenase (G6PD) status seem to be important
factors determining the severity of the methemoglobinemia and carboxyhemoglobinemia. Therefore,
G6PD status should be determined before medications such as hydroxychloroquine are administered.
In conclusion, MetHb and COHb can be elevated in COVID-19 patients and should be checked
routinely in order to provide adequate medical treatment as well as to avoid misinterpretation of
fingertip pulse oximetry readings, which can be inaccurate and unreliable in case of elevated MetHb
and COHb levels in the blood.
Keywords: COVID-19; SARS-CoV-2; methemoglobin; methemoglobinemia; carboxyhemoglobin;
carboxyhemoglobinemia
1. Introduction
After a series of acute respiratory syndrome cases of unknown cause were reported in
December 2019 in Wuhan, Hubei province, China, genome sequencing of lower respiratory
tract samples from patients showed the presence of a novel human coronavirus (severe acute
respiratory syndrome coronavirus 2, SARS-CoV-2) [1,2] and the disease associated with SARS-
CoV-2 was termed Corona Virus Disease 2019 (COVID-19). On 11 March 2020, the World
Health Organization (WHO) declared the outbreak a global pandemic. Until now (Novem-
ber 2020), more than 47 million COVID-19 cases have been reported globally by the WHO.
While most of SARS-CoV-2 infected subjects are pauci-symptomatic [3] and about 15%
asymptomatic [4], in some individuals the disease can develop to a more serious respiratory
illness requiring hospitalization and intensive care treatment when it progresses to a critical
illness involving pneumonia with hypoxemia, acute respiratory distress syndrome and
severe systemic inflammation [5]. The infection-fatality rate (IFR) is determined currently
J. Clin. Med. 2021, 10, 50. https://doi.org/10.3390/jcm10010050 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 50 2 of 15
to be 0.68% (0.53–0.82%) [6], with a decrease in the number to be expected due to the
current increased divergence between the infection and death rates globally. The IFR is a
function of age, with an IFR of <0.01% for subjects under 25 years of age and a log-linear
increase of the IFR for subjects older than 30 years [7].
As critically ill patients are often found to form methemoglobin (MetHb) [8–10] and
carboxyhemoglobin (COHb) [11,12], MetHb and COHb formation might also be relevant
in case of COVID-19. MetHb is formed when the ferrous iron (Fe2+) of the heme group
of hemoglobin (Hb) is oxidized to ferric iron (Fe3+). The ferric iron of MetHb is unable to
bind oxygen (O2). Thus, the O2 dissociation curve is left-shifted, making it more difficult to
release O2 and to provide proper tissue oxygenation. The formation of MetHb also results
in less Hb available for O2 binding and transport.
MetHb is continuously produced under physiological conditions in a limited amount
due to auto-oxidation, but it is rapidly converted back to Hb primarily by nicotinamide
adenine dinucleotide (NADH)-dependent cytochrome-b5 reductase (also known as MetHb
reductase) and to a limited degree also by ascorbate and glutathione [13]. COHb is formed
when Hb and carbon monoxide (CO) interact; CO binds to heme molecules 240 times
more than O2. The resulting COHb limits the blood’s O2-carrying capacity [14]. In healthy,
non-smoking individuals, MetHb is in the range of 0.67 ± 0.33% [15] and COHb in the
range of 0.5–1.5% [16].
The aim of our study was to summarize the currently available published study results
(case reports and cross sectional studies) on MetHb and COHb in patients with COVID-19.
2. Methods
The literature research was performed with MEDLINE (PubMed) and Google Scholar
using search terms connected with Boolean operators. Two separate searches were per-
formed for MetHb and COHb to make the literature research process simpler. For case
one (MetHb and COVID-19) the keywords “methemoglobinemia”, “methemoglobinemia”,
”methemoglobin”, “methaemoglobin”, “COVID-19” and “COVID19” were used; for case
two (COHb and COVID-19) they were “carboxy-hemoglobinemia”, “carboxyhaemoglobi-
naemia”, ”carboxyhemoglobin”, “carboxyhaemo-globin”, “COVID-19” and “COVID19”.
Relevant studies published in 2020 were searched. In addition, the reference lists of relevant
published articles were also manually searched for additional articles.
The result of the literature research was screened for articles (studies or case reports)
that report measurement of MetHb or COHb in COVID-19 patients. The exclusion criteria
were articles not reporting MetHb or COHb measurements or articles published in non-
academic journals, reviews, dissertations or conference abstracts. Articles published on
preprint servers were included.
3. Results
3.1. Literature Search Results
For the case of MetHb and COVID-19, a total of 201 articles were initially retrieved
from PubMed (n = 6) and Google Scholar (n = 196) using the literature search strategy
mentioned above. Based on the inclusion and exclusion criteria, seven duplicates were
removed and 187 articles were excluded after abstract review. After the full set of remaining
articles was screened, seven reports were finally included in the present study [17–23].
The study selection process is shown in Figure 1a.
For the case of COHb and COVID-19, 73 articles were retrieved from PubMed (n = 1)
and Google Scholar (n = 72), one duplicate was removed and 68 articles were excluded
after abstract review, leading to three articles that were finally included in the present
study [20,24,25]. The study selection process is shown in Figure 1b.
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Figure 1. Flow diagram of the literature search process according to the PRISMA criteria. PRISMA: Preferred Reporting
Items for Systematic Reviews and Meta-Analyses.
3.2. Characteristics of the Included Studies
From the seven studies included in this review for the case of MetHb and COVID-19,
two were cross-sectional studies [19,21] and five case reports [17,18,20,22,23]. The case
descriptions reported findings of one single patient [17,20,22,23] or three patients [18].
Five studies were published in journals [17,18,20–22] and two on the preprint server
medRxiv (medrxiv.org) [19,23].
For the case of the three studies concerning COHb and COVID-19, two were cross
sectional studies [24,25] and one a case report [20]. Two of the studies were published in
journals [20,25] and one on the preprint server Research Square (researchsquare.com) [24].
3.3. Summary of the Studies: MetHb and COVID-19
Kuipers et al. reported the case of a 56-year-old Afro-Caribbean man with a medical
history of type 2 diabetes presenting to the emergency department with myalgia, dry cough
and a peripheral O2 saturation (SpO2) of 94%, but not fever. COVID-19 was confirmed by
a positive SARS-CoV-2 PCR test result. Bilateral ground glass opacities of the chest were
detected by CT. In the following days, an increasing need for O2 administration was noted,
SpO2 dropped to 83% and mechanical ventilation was initiated as well as treatment with
chloroquine. Twelve hours later, hemolysis and an abnormally high level of MetHb (9.1%)
were noted (Figure 2a). The patient was then treated with three units of packed red blood
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cells in the following 48 h and ascorbic acid (vitamin C) intravenously four times a day
for two days, resulting in a normalization of MetHb levels within six days. A suspected
glucose-6-phospate dehydrogenase (G6PD) deficiency was confirmed by genetic analysis.
Figure 2. Visualization of (a) methemoglobin (MetHb) and (b) carboxyhemoglobin (COHb) values of COVID-19 patients
reported in the literature. The green shaded areas refer to the reference ranges for healthy individuals in case of MetHb
(0.67 ± 0.33% for healthy non-smokers [15]) and COHb (0.5–1.5% for healthy non-smokers [16]). Different subjects reported
in the case reports are marked with “#”, and red lines with arrows indicate the development of subject-specific values
during the course of the disease.
Al-Aamri described a case of a 10–15-year-old Saudi girl (the exact age was appar-
ently unknown) who was admitted to the hospital with a clinical presentation similar to
Kawasaki disease shock syndrome, which she developed 22 days after a routine SARS-CoV-
2 test that turned out to be positive. Her condition deteriorated in the following days while
receiving multiple medications (Azithromycin, Favipiravir, Methylprednisolone, Enoxa-
parin, intravenous immunoglobulin, Aspirin, Tocilizumab, Norepinephrine, Epinephrine,
Furosemide, Milrinon, insulin, blood transfusion, fresh frozen plasma, vitamin K and
ascorbic acid), finally leading to her death at day 33. Intubation was performed and venti-
lation was started on day 29. The report mentioned that MetHb was 0.5–1.9% (min, max),
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implying that multiple MetHb measurements were made (Figure 2a). Exactly when the
measurements were performed during the disease course was not mentioned. Genetic anal-
ysis confirmed a G6PD deficiency.
Palmer et al. reported the case of a 62-year-old Afro-Caribbean man with a medical
history of type 2 diabetes and hypertension, presenting at the hospital after five days of
fever, dyspnea, vomiting and diarrhea. A chest radiograph showed bilateral infiltrates,
a kidney injury was diagnosed and a SARS-CoV-2 test returned positive. On admission,
MetHb was 1.2%. The patient was treated with crystalloid fluid, O2 therapy, insulin,
two blood transfusions, amoxicillin/clavulanic acid, heparin, amlodipine, metformin,
and folic acid. The patient was discharged 22 days after admission. On day six, the highest
MetHb value was noted (6.8%). A suspected G6PD deficiency was confirmed. The time-
course of MetHb during the stay in the hospital is visualized in Figure 3d.
Faisal et al. [20] published a report on a case of a 74-year-old Afro-American man
with a medical history of prostate cancer, hypertension and hyperlipidemia that presented
to the clinic after seven days with fever, cough and progressively worsening shortness
of breath. On admission, the person showed tachypnea, a SpO2 of 90% and returned
a positive SARS-CoV-2 test result. Chest computed tomography (CT) revealed bilateral
perihilar and right lower lobe opacities. After treatment with O2 therapy, azithromycin
and hydroxychloroquine, his health worsened, and he was intubated and mechanically
ventilated. He was then treated with lopinavir-ritonavir, ribavirin, tocilizumab, antibiotics,
thiamine, hydrocortisone, ascorbic acid and norepinephrine. On day 15, hypoxia was noted
(SpO2: 80–90%), but arterial blood gas analysis showed an arterial Hb saturation (SaO2) of
100%. MetHb was increased (6.3%). Treatment continued with intravenous ascorbic acid,
hydroxocobalamin, and intravenous methylene blue. MetHb raised to 15.9%. After further
treatment with intravenous methylene blue and red blood cell transfusion MetHb declined
to 2–4%. The patient slowly recovered and was discharged on day 31 after admission.
No genetic testing of a G6PD deficiency was performed.
Naymagon et al. [18] reported three cases of COVID-19 patients with MetHb measure-
ments. The first case was a 50-year-old SARS-CoV-2 positive man with no medical history
presenting with acute hypoxic respiratory failure in the clinic. He received hydroxychloro-
quine, azithromycin and ceftriaxone, and mechanical ventilation. He showed persistently
low SpO2 values despite being mechanically ventilated. MetHb values increased steadily,
peaking at 10.6% on day six (Figure 2a). Treatments with methylene blue and ascorbic acid
normalized MetHb and his clinical status improved. A genetic analysis of G6PC deficiency
was not done. The second case was a 52-year-old SARS-CoV-2 positive morbidly obese man
with diabetes mellitus, admitted to the hospital due to acute hypoxic respiratory failure.
He received hydroxychloroquine, azithromycin, cefepime, vancomycin, and apixaban,
and was mechanically ventilated. A persistently low SpO2 was recognized and testing for
MetHb resulted in a value of 22% (Figure 2a). He received methylene blue and ascorbic
acid, but his MetHb increased to >30%. After receiving red blood cell transfusion, MetHb
decreased to 2.9%. No genetic analysis of G6PD deficiency was performed. The third case
was a 54-year-old SARS-CoV-2 positive man with diabetes mellitus admitted to the hospital
due to acute hypoxic respiratory failure. He received azithromycin and hydroxychloro-
quine and was mechanically ventilated. He demonstrated persistent hypoxia and a MetHb
of 13.7%. After receiving methylene blue, MetHb did not improve and increased to 18.8%.
Shortly after, the patient died. Genetic testing revealed G6PD deficiency.
Alamdari et al. [21] investigated MetHb levels in 25 healthy individuals and 25 COVID-
19 patients from Iran. Subjects with G6PD deficiency were excluded from the study. Pa-
tients showed a statistically significantly higher MetHb concentration in their blood compared
to healthy controls (16.4 ± 9.1% vs. 2.5 ± 0.9%). According to the five cases reported in
detail in this publication, the medical standard treatment included azithromycin and hy-
droxychloroquine. To treat the elevated MetHb, methylene blue, ascorbic acid and N-acetyl
cysteine were administered. The authors concluded that it is crucial to treat the elevated
MetHb in critically ill COVID-19 patients. Soltan et al. [19] used an artificial intelligence
J. Clin. Med. 2021, 10, 50 6 of 15
method and data from 115,394 emergency presentations and 72,310 admissions to a large UK
teaching hospital group to predict COVID-19 cases. The data used were routinely collected
data typically available within one hour during emergency presentations and admissions to
hospital. Data from COVID-19 patients (n = 534) and pre-pandemic controls (n = 114,957)
were included in the final analysis. Interestingly, while MetHb was a relevant parameter
to be included in the models (see Figure 3a,b), MetHb was similar in the COVID-19 cohort
compared to pre-pandemic controls (0.62% (0.4–0.8%) vs. 0.88% (0.6–1.1%)).
Figure 2a visualizes the summarized MetHb values reported by the seven publications.
Figure 3. (a,b) Relative feature importance in predicting COVID-19 according to the
study of Soltan et al. [19]. Two models were built, one with data based on emergency
presentation (a) and one with data based on hospital admission. MetHb was a relevant
parameter in both models (indicated in red). (c) COVID-19 non-survivors (n = 22) show
a steeper and higher increase of COHb during the curse of the disease compared to
COVID-19 survivors (n = 41), according to the study of Paccaudi et al. [24]. The two COHb
time-series are statistically significantly different. The yellow bar refers to the COHb
reference ranges for healthy non-smokers [16]. (d) Time-course of MetHb of a COVID-19
patient reported by Palmer et al. [22]. The yellow bar refers to the MetHb reference range
for healthy non-smokers [15]. The figures show data extracted from the original figures of
the respective publications.
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3.4. Summary of the Studies: COHb and COVID-19
In their case report on a 74-year-old Afro-American man with COVID-19 already detailed
in Section 3.2, Faisal et al. [20] described that, when the patient showed hypoxia and a MetHb
concentration of 6.3%, COHb was 3.2%, i.e., above the normal reference range. After the
patient was treated with intravenous ascorbic acid, hydroxocobalamin and methylene blue,
COHb normalized (value not given in the report), while MetHb continued to rise.
Pawlowski et al. [25] found that, when comparing 246 SARS-CoV-2 PCR-positive
patients to propensity-matched 2460 SARS-CoV-2 PCR-negative patients, COHb at clinical
presentation was actually slightly, but significantly, higher in the SARS-CoV-2 PCR-negative
population (0.99 vs. 0.57%) (Figure 2b). The same trend was seen until seven to nine days
after admission.
Paccaudi et al. [24] analyzed the data of 63 patients admitted in the hospital for severe
COVID-19 and found that, while COHb was not different for survivors in comparison to
non-survivors (1.10 ± 0.50% vs. 0.95 ± 0.24%) (Figure 2b), COHb increased to statistically
significantly higher values during the course of the hospital stay in non-survivors compared
to survivors (see Figure 3c), leading the authors to conclude that a greater increase in COHb
over time seems to represent a relevant marker of COVID-19 severity and seems to play a
role in the determination of the survival probability of a COVID-19 infection.
Figure 2b visualizes the MetHb values reported by the seven publications summarized.
4. Discussions
4.1. Is MetHb Increased in COVID-19 Patients?
According to the case reports of Kuipers et al. [17], Al-Aamri et al. [23], Palmer et al. [22],
Faisal et al. [20], and Naymagon et al. [18], MetHb values for COVID-19 patients were above
the reference range of 0.67 ± 0.33% for healthy non-smokers (Borland et al. 1985) with the
highest MetHb value of >30% for a patient reported by Naymagon et al. [18].
In the case reports of Palmer et al. [22], Faisal et al. [20] and Naymagon et al. [18], MetHb
increased in the COVID-19 patients during the course of the disease. Data of multiple MetHb
measurements during the disease course were published by Palmer et al. [22], showing a rise
of MetHb to a peak after a few days and a decline after treatment (Figure 3d).
COVID-19 patients (n = 25) were shown to have a higher MetHb compared to healthy
individuals (n = 25) as demonstrated in a cross-sectional study by Alamdari et al. [21],
supporting the findings reported. However, the cross-sectional study of Soltan et al. [19]
with a large cohort (534 COVID-19 patients and 114,957 pre-pandemic controls) showed no
statistically significant differences in the MetHb values despite the fact that MetHb was
an important parameter for the prediction of COVID-19 based on the algorithm the group
developed. This apparent discrepancy between the result of Alamdari et al. and Soltan et al.
seems to be due to the following reason: the MetHb data used by Soltan et al. stem from the
time of emergency presentations and admission to hospital, whereas the MetHb data from
Alamdari et al. were collected from the whole time-course of the hospital stay. Since MetHb
has been reported to increase during the development of the disease [18,20,22], the results
of Soltan et al. are understandable since, during the MetHb sampling time at the beginning
of the disease, MetHb is not necessarily increased (at least at the group level).
In conclusion, MetHb seems to be elevated in COVID-19 patients, with a dynamic
following the disease progression.
4.2. Is COHb Increased in COVID-19 Patients?
A significantly higher COHb value in COVID-19 patients compared to reference value
of healthy non-smokers (0.5–1.5% for healthy non-smokers [16]) was found in two of the
three available reports on COHb and COVID-19 published so far. In the case report of Faisal
et al. [20], COHb was 3.2% during the disease course. According to the study of Paccaud
et al. [24], COHb rose above the reference range on about the 10th day after hospitalization.
Interestingly, this study also clearly demonstrated that at admission, COHb was in the
normal range for the COVID-19 patients, while COHb was statistically significantly more
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elevated on the 31st day of the hospital stay in COVID-19 patients compared to patients
suffering from other illnesses. These results are in line with the results of Pawloski et al. [25],
who reported that their COVID-19 cohort did not show COHb values above the reference
range during the time-span investigated (admission until day seven to nine of the stay).
Since Paccaud et al. found that it needs about 10 days until COHb is above the reference
range, the too short time-span used by Pawloski et al. to compare COHb values from
COVID-19 patients and controls might explain the apparent discrepancy.
In conclusion, COHb can be elevated in COVID-19 patients, especially from about two
weeks after onset of the disease. The magnitude of COHb elevation seems to be correlated
with the survival probability of the COVID-19 patients.
4.3. Possible Reasons for Methemoglobinemia in COVID-19 Patients
There are several factors relevant to explain why methemoglobinemia and carboxyhe-
moglobinemia can be present in COVID-19 patients. The SARS-CoV-2 infection, the indi-
vidual constitution and the medical treatment seem to be the major ones.
It is well known that several medical drugs can increase MetHb concentration in the
blood as a side-effect [26,27]. A recent review reports the early recognition, pathophysiol-
ogy, and management of methemoglobinemia in the intensive care unit [28]. Chloroquine
is such a drug for which reports were published regarding induced methemoglobine-
mia due to its intake [29–31]. Both chloroquine and hydroxychloroquine (a derivative
of chloroquine) are currently used to treat COVID-19, while debate is ongoing about
their effectiveness and safety [32–39]. Moderately certain evidence suggests that hydroxy-
chloroquine lacks efficacy in reducing short-term mortality in patients hospitalized with
COVID-19 or at risk of hospitalization in outpatients with COVID-19.
A G6PD deficiency can enhance the probability of methemoglobinemia induced by
oxidizing drugs, such as hydroxychloroquine [40]. However, a very recent experimental
animal study suggests that short-course high doses of hydroxychloroquine do not induce
methemoglobinemia or clinically significant hemolytic anemia or organ damage in a murine
model of G6PD deficiency [41]. Clinically, chronic hemolytic anemia associated with G6PD
deficiency is rare [42]. So far, no evidence of hemolysis was observed in patients with
G6PD deficiency when exposed to low doses of hydroxychloroquine [43]. The first case of
severe hemolytic crisis was found in a seriously ill COVID-19 patient with G6PD deficiency
following treatment with high doses of hydroxychloroquine [44]. Several other cases have
subsequently been reported by others [45–47]. Nevertheless, Mastroianni et al. [47] and
Afra [48], concerning hydroxychloroquine use in G6PD-deficient patients, have indicated
that it is difficult to assess the relationship between hydroxychloroquine and hemolysis
in COVID-19 patients. With the global spread of COVID-19, especially in regions with a
high prevalence of G6PD deficiency, these cases should alert physicians to the possible
correlation between G6PD-deficiency and hydroxychloroquine treatment.
In the reports on MetHb and COVID-19 summarized in Section 3.2, the use of chloro-
quine or hydroxychloroquine is described. In the case reported by Kuipers et al. [17],
the subject received chloroquine and had a G6PD deficiency; hydroxychloroquine was
administered to the subject reported by Faisal et al. [20] (the G6PD status was not reported);
and in the three cases reported by Naymagon et al. [18] all received hydroxychloroquine,
while one subject was tested for G6PD deficiency and was positive. In the cases reported
by Al-Aamri et al. [23] and Palmer et al. [22], the patients did not receive chloroquine and
hydroxychloroquine, but the patient described by Al-Aamri et al. had a G6PD deficiency.
A G6PD deficiency is not only relevant with respect to the reaction to antiviral oxidizing
drugs, but also for the effects of the drug methylene blue administered to treat the methe-
moglobinemia. Methylene blue may be ineffective in patients with a G6PD deficiency since
they lack sufficient reduced nicotinamide adenine dinucleotide phosphate (NADPH) to
reduce methylene blue to leuko-methylene [49,50].
Despite the obvious effect of oxidizing drugs on the formation of MetHb, it can also
be formed as a byproduct of a physiological reaction in the form of an adaptive increased
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nitric oxide (NO) signaling due to an acute anemia [51]. Anemia can be associated with
an infection and/or a systemic inflammatory reaction, termed “anemia of inflammation”,
as part of the physiological reaction to the disease [52,53]. According to a study by Bellmann-
Weiler et al. [54] on 259 hospitalized patients with COVID-19, 24.7% were anemic on admission,
with the majority suffering from anemia of inflammation (68.8%). During hospitalization,
the percentage of patients with anemia increased (around 68.8% at day 7). A significantly
higher mortality during hospitalization was also found in those with anemia upon admis-
sion. Anemia is associated with an increased NO expression, leading to vasodilation and
thus preventing tissue hypoxia, but also causing increased NO-based oxidation of Hb to
MetHb [51]. Interestingly, anemia, and drops in total Hb (tHb), have been reported in COVID-
19 patients [22,55,56].
An anticorrelated development of tHb levels and MetHb levels in a COVID-19 patient
has been reported [22], in line with the pathway described by Hare et al. [51] of an NO-
induced MetHb increase caused by anemia. The role of MetHb as a marker of anemic stress
has been also been validated in a study investigating MetHb changes in patients undergoing
heart surgery [57]. While “anemia of inflammation” is associated with methemoglobinemia,
iron-deficient anemia seems to be a further risk factor for acquired methemoglobinemia by
enhancing red blood cell oxidative stress [58]. The occurrence of methemoglobinemia due
to a viral infection has been reported for several types of infection [59–61]. For example,
the activity of MetHb reductase has been shown to be negatively affected by infections
with Plasmodium yoelii nigeriensis [62,63] or Plasmodium knowlesi [61].
The fact that the severity of the methemoglobinemia observed in COVID-19 patients
was dependent on the subject firstly reflects the different disease severities of the patients
but is also most probably due to the physiological constitution of the subjects before the
disease, related to their medical history, their overall fitness and age. The age factor seems
to be of particular interest since, for example, erythrocytes from elderly humans are more
easily affected by oxidative stress, facilitating the formation of MetHb [64].
MetHb can have proinflammatory properties. For example, it activates the NF-κB
pathway in endothelial cells associated with chemokine (IL-8) and cytokine (IL-6) produc-
tion [65]. The activation of the NF-κB and MAPK pathways with subsequent release of the
chemokines IL-8 and the chemokine monocyte chemoattractant protein-1 (MCP-1) has also
been observed in endothelial cells exposed to MetHb [66]. This underlines that an elevation
of MetHb in the blood has an effect on cytokine/chemokine production—a fact that might
be of particular relevance for COVID-19 since a “cytokine storm” has been observed in
severe courses of the disease [67–70]. At the same time, it must also be borne in mind that
hypoxia also causes the production of cytokines and cytokines, like IL-8 and IL-6 [71,72].
4.4. Possible Reasons for Carboxyhemoglobinemia in COVID-19 Patients
Since the blood COHb concentration reflects the balance between endogenous CO
production and CO elimination, carboxyhemoglobinemia in COVID-19 patients could indicate
an increased endogenous CO production and/or a decreased CO elimination ability.
Endogenous CO production is mainly due to the inducible heme oxygenase (HO-1)
enzyme, which catalyzes the heme moiety of Hb to biliverdin and liberates CO during this
process. CO can then react with Hb, leading to the formation of COHb. HO-1 is upregulated in
case of oxidative stress and inflammation which leads to increased COHb production [73,74].
Hemolytic anemia facilitates the production process of COHb so that an increased COHb
blood level can be seen as a manifestation of hemolytic anemia [75]. Since anemia and
hemolysis possibly occur during the course of disease in COVID-19 patients [17,18,22,54],
hemolytic anemia may also be responsible for their COHb elevation. Because intracellular
NADPH depletion and consecutive oxidative stress with damaged erythrocytes (hemolysis)
is typical for G6PD deficiency, it is not surprising that G6PD deficiency in COVID-19 patients
seems to be associated with elevated MetHb and COHb levels [20].
A decreased CO elimination occurs when respiration is impaired. As COVID-19 pa-
tients are characterized by respiratory impairment, increased COHb levels can be explained
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by reduced CO elimination and thus a higher probability of COHb formation. Mechanical
ventilation may also be relevant since, for example, an increase in the inspired O2 frac-
tion leads to an increase in exhaled CO concentration [76], possibly leading to a reduced
COHb production.
Interestingly, while elevated COHb levels seem to be correlated with COVID-19
severity, intensive care mortality from other causes was found to be associated with too
low [12,77] and both too low or too high COHb values [11], indicating the existence of an
optimal COHb level for optimal physiological functioning [12]. HO-1 upregulation, associ-
ated with elevations of COHb, has immunomodulatory and anti-inflammatory effects [78].
Inflammation changes COHb levels in the blood in a complex time-dependent manner as
demonstrated by experimental endotoxemia in humans [79], highlighting the non-linear
relationship between inflammation, disease severity and COHb levels.
4.5. Methemoglobinemia and Carboxyhemoglobinemia in COVID-19 Patients: Consequences for
Patient Monitoring and Treatment
Methemoglobinemia and carboxyhemoglobinemia seem to play a role in the patho-
physiology of COVID-19, especially in more severe cases of the disease.
While the ability to determine MetHb and COHb levels is normally routinely available
in clinical settings via blood gas analysis, there are only a few commercial monitoring
devices that enable continuous non-invasive measurement of MetHb and COHb values,
mainly the fingertip pulse CO-oximeters by Masimo and Nonin. These devices do not
normally feature in standard clinical equipment. This is unfortunate since continuous
monitoring of tHb, MetHb and COHb levels could be helpful in guiding the treatment and
monitoring of COVID-19 disease progression.
From the reports discussed in Sections 3.2 and 3.3 it is clear that the determination
of MetHb and COHb is especially warranted when patients are treated with oxidizing
drugs such as chloroquine and hydroxychloroquine. This is even more important when
the patients have a confirmed G6PD deficiency.
For the interpretation of COHb values, the smoking status of the patient needs to be
considered as smokers have a higher COHb concentration in the blood than non-smokers
(2.7 ± 2.6% [80], 3.26 ± 2.2% [15], 5.12 ± 2.25% [81], 2.1 ± 1.02% [82]).
Knowledge of MetHb and COHb levels in the blood of COVID-19 patients is also
relevant to prevent misinterpretations of arterial oxygen saturation values measured with
fingertip pulse oximetry (SpO2). This is because MetHb and COHb interfere with the
measurement of SpO2. An overestimation of the true arterial oxygenation (SaO2) can occur.
In case of a decrease in SaO2 and an increase in MetHb or COHb, SpO2 will diverge more
from SaO2 the higher the MetHb and COHb concentration (see Figure 4). For example,
assuming a MetHb concentration of around 25% (corresponding to the upper end of the
confidence interval of MetHb values in COVID-19 patients reported by Alamdari et al. [21])
and an assumed decrease of SaO2 to 75%, the SpO2 measurements would indicate a falsely
too high SpO2 of about 88%. Measurement with pulse CO-oximetry instead of pulse
oximetry would circumvent this problem since pulse CO-oximetry is able to non-invasively
measure MetHb, COHb, tHb, and the correct SpO2. [83–85].
Methemoglobinemia and carboxyhemoglobinemia cause a shift in the Hb dissociation
curve to the left, leading to a reduced ability of O2 to be released from Hb, which can result in
hypoxia. Methemoglobinemia and carboxyhemoglobinemia need to be monitored and treated,
therefore. Therapies of methemoglobinemia in COVID-19 patients have been performed with
methylene blue and, in some cases, combined with blood transfusions [18,20,21].
The fact that COVID-19 patients could show hypoxemia without having dyspnea, i.e.,
silent hypoxia or so-called “happy” hypoxia [88–90], seems to be primarily due to (i) a
blunted response of the respiratory control system to hypoxia which is prevalent in older
subject and those with diabetes, (ii) changes in arterial CO2 levels, (iii) temperature-induced
shifts in the O2 dissociation curve, and (iv) the inaccuracy of pulse oximeters at low SpO2
values, as highlighted by Tobin et al. [89,91].
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Figure 4. The impact of MetHb and COHb on SpO2 measured with pulse oximetry. (a) Blood MetHb vs. SpO2 and blood
Hb O2 saturation (O2Hb). Data extracted from Barker et al. [86]. (b) Blood COHb vs. SpO2 and blood O2Hb saturation.
Data extracted from Barker et al. [87]. In both studies, measurements were made on dogs; the inspired O2 fraction (FIO2)
was 1, SpO2 was measured on the tongue with a pulse oximeter (Nellcor N-100, USA) and COHb, MetHb and O2Hb
saturation with a CO-oximeter (IL-282, Instrumentation Laboratories, Bedford, MA, USA). The figures show data extracted
from the original figures of the respective publications.
For hospitals it might be also relevant to re-evaluate their water disinfection procedure
since the use of a hydrogen peroxide/silver ion preparation for treating the water supplied
in the hospital caused elevated levels of MetHb in the severely ill patients (treated with
daily hemodialysis/hemodiafiltration) drinking this water [92]. When blood transfusions
are given to COVID-19 patients, it should be also considered that the MetHb content of the
banked blood increases over time [93] and that banked blood from smoking donors can
have a relatively high COHb concentration [94], representing a possible risk for critically
ill patients. It makes sense therefore to test the banked blood for MetHb and COHb
concentration levels before administering it to patients, especially in case of COVID-19.
5. Summary and Conclusions
We identified and analyzed nine studies that reported information about MetHb and
COHb values of COVID-19 patients. 86% (6/7) studies reported an increased MetHb con-
centration above the normal reference range, and one study did not find such an increase.
Regarding COHb, 67% (2/3) studies reported an increase, and one found no elevated
COHb. As highlighted by the observations of Palmer et al. [22] and Paccaud et al. [24],
the time of MetHb and COHb measurement during the course of the disease is critical,
since MetHb and COHb seem to generally increase in hospitalized COVID-19 patients.
The type of medical treatment is also of importance since some drugs currently used
to treat COVID-19 have a high oxidizing potential provoking methemoglobinemia and
carboxyhemoglobinemia.
Monitoring of MetHb and COHb values routinely, and if possible, continuously with
non-invasive pulse CO-oximeters, seems to be warranted for optimal COVID-19 disease
monitoring. The tHb, MetHb and COHb concentration in the blood is also relevant for a
correct interpretation of SpO2 values measured with fingertip pulse oximetry.
Future studies should investigate in detail the link between MetHb/COHb levels in
COVID-19 patients and the clinical outcome. As both values were found to be indepen-
dently related to mortality in critically ill patients [77], the assessment of both parameters
is necessary.
In conclusion, MetHb and COHb seem to be elevated in COVID-19 patients, with a
dynamic following the disease progression. MetHb and COHb measurements should be
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regularly assessed in COVID-19 patients, for example with blood gas analysis (which in-
cludes a CO-oximetry module), conventional CO-oximeters or by continuous CO-oximetry.
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